Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for KalVista Pharmaceuticals, Inc. (KALV : NSDQ)

• Company Description    KalVista Pharmaceuticals, Inc. is a pharmaceuticals company. It engages in discovery, development and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product portfolio consist hereditary angioedema and diabetic macular edema, KVD818 and KVD001, which are in clinical stage. KalVista Pharmaceuticals, Inc., formerly known as Carbylan Therapeutics, Inc., is headquartered in Cambridge, United States. Number of Employees: 270

• Price / Volume Information    Yesterday's Closing Price: $16.90 Daily Weekly Monthly 20 Day Moving Average: 1,413,663 shares Shares Outstanding: 50.55 (millions) Market Capitalization: $854.23 (millions) Beta: -0.14 52 Week High: $17.30 52 Week Low: $7.30 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 13.73% 11.32% 12 Week 29.01% 26.68% Year To Date 99.53% 72.16%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 200 CROSSING BOULEVARD - FRAMINGHAM,MA 01702 USA ph: 857-999-0075 fax: 866-553-3269 ir@kalvista.com http://www.kalvista.com

• General Corporate Information    Officers Benjamin L. Palleiko - Chief Executive Officer Brian J.G. Pereira - Chairman Brian Piekos - Chief Financial Officer William Fairey - Director Laurence Reid - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 483497103 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: - Share - Related Items Shares Outstanding: 50.55 Most Recent Split Date: 11.00 (0.07:1) Beta: -0.14 Market Capitalization: $854.23 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.84 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.77 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 5.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 9.03% Last Dividend Paid: NA - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 50.23 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -1.10% vs. Previous Quarter: 17.86% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: 860.17% ROE 09/30/25 - -214.88 06/30/25 - -216.92 03/31/25 - -151.08 ROA 09/30/25 - -81.87 06/30/25 - -118.15 03/31/25 - -109.16 Current Ratio 09/30/25 - 7.22 06/30/25 - 5.35 03/31/25 - 10.44 Quick Ratio 09/30/25 - 7.21 06/30/25 - 5.35 03/31/25 - 10.44 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -1,268.65 06/30/25 - -12,871.88 03/31/25 - - Book Value 09/30/25 - 0.34 06/30/25 - 1.91 03/31/25 - 2.92 Inventory Turnover 09/30/25 - 15.91 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 8.18 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 89.11 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©